The Preclinical Research Development program consults with investigators on the scientific information required to support an Investigational New Drug application to FDA. This includes characterization of the product, animals models of safety or efficacy, or toxicology. In addition, the ITHS Preclinical Research Development team will consult on the content of the IND application and FDA interactions in general. This support currently includes review of pre-IND and IND applications.
In some cases it may be advisable to present your program to the Drug and Device Advisory Committee DDAC for preliminary review of the preclinical data supporting the application.